Dental membranes and bone graft substitutes are used for dental bone regeneration procedures in patients affected by oral health disorders such as periodontal diseases and oral cancer. Dental membranes are used alongside dental bone grafts to allow cell proliferation. Major factors contributing to growth of the dental membrane and bone graft substitutes market are growing number of oral health issues, increasing product launches, and rising dental health expenditure. For instance, in April 2018, Geistlich Pharma North America Inc. announced the launch of two new resorbable collagen membranes Geistlich Bio-Gide Compressed and Geistlich Bio-Gide Shape.
The U.S. dental membrane and bone graft substitutes market is estimated to be valued at US$ 171.9 million in 2021 and is expected to exhibit a CAGR of 9.9% during the forecast period (2021-2028).
Figure 1. U.S. Dental Membrane and Bone Graft Substitutes Market Share in Terms of Value (US$ Mn), By Product Type, 2021
Increasing oral health diseases is expected to drive the market growth over the forecast period.
Increasing oral health diseases such as cavities and gum disease is the leading factor for growth of dental membrane and bone graft substitutes market across the globe. The factors leading to oral health issue includes unhealthy diet, tobacco use, excess alcohol consumption, and poor oral hygiene. For instance, according to the Centers for Disease Control and Prevention report 2019-2020, in the U.S., more than a quarter (26%) of adults had untreated tooth decay and almost half (46%) of all adults 30 years and older had signs of gum disease.
|Base Year:||2020||Market Size in 2021:||US$ 171.9 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||9.9%||2028 Value Projection:||US$ 333.6 Mn|
|Companies covered (8):||
Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, and Sun Pharmaceutical Industries Ltd.
|Restraints & Challenges:||
Figure 2. U.S. Dental Membrane and Bone Graft Substitutes Market Share (%), By Application, 2021
Increasing product launches is expected to drive the market growth during the forecast period.
Increasing demand for efficient implants and membrane for dental restoration due to increasing oral health issues is expected to propel growth of the U.S. dental membrane and bone graft substitute market during the forecast period. In order to cater to increasing demand, manufacturers are focusing on developing new and highly efficient products included in implants and restoration. For instance, in February 2019, Zimmer Biomet Holdings, a global healthcare company, announced the expansion of its dental product portfolio to include non-resorbable membranes and sutures. The new OsseoGuard non-resorbable product line includes dense PTFE (polytetrafluoroethylene) membranes in multiple texture variations as well as titanium mesh and PTFE sutures. OsseoGuard products are currently available in the U.S. and Canada.
U.S. Dental Membrane and Bone Graft Substitutes Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic is expected to hamper growth of the U.S. dental membrane and bone graft substitutes market during the forecast period. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 43 million cases and 0.69 million deaths due to coronavirus (COVID-19) were reported up till September 23, 2021, across the U.S.
Furthermore, the decrease in patients visiting dental clinics is a major challenge faced during the pandemic. For instance, according to the report published by the American Dental Association (ADA), April 2020, the COVID-19 pandemic had a significant impact on the dental care industry in the U.S. Over three-fourths of dental practices in the U.S. saw only emergency patients, and another 18% were completely closed. Moreover, according to the same source, the vast majority of dentists reported that their total collection volume was less than 5% of what is typical. Moreover, according to ADA's analysis, there was a 66% reduction in the U.S. dental spending in 2020 compared to pre-pandemic projections, which could lead to 32% reduction of dental spending in 2021.
U.S. Dental Membrane and Bone Graft Substitutes Market: Restraint
The high cost of dental membranes and bone grafts is expected to impede the U.S. dental membranes and bone graft substitutes market growth over the forecast period. The cost of a bone graft can vary substantially depending on the case and the condition of the patient’s jawbone. The typical costs associated with simple bone grafting for dental purposes using synthetic bone can cost between US$ 300 and US$ 800 for a single implant area.
Major players operating in the U.S. dental membrane and bone graft substitutes market include Institut Straumann AG, Nobel Biocare Services AG, Geistlich Pharma AG, Zimmer Biomet Holdings, Inc., Dentsply Sirona, Inc., BioHorizons, Inc., NovaBone Products, LLC, Collagen Matrix, Inc., Maxigen Biotech, Inc., Osteogenics Biomedical., Medtronic, and OUSIA.
Bone grafting is a procedure used in dentistry to increase the density and volume of natural jawbone tissue. Natural bone grows and eventually completely replaces the graft material. Natural bone grafts such as allografts consists of demineralized bone matrix, which has better osteoconductive and osteoinductive activity. Moreover, synthetic bone grafts include grafts made of ceramic, composite, polymer, and bone morphogenetic proteins (BMPs). Furthermore, another essential product is dental membrane, which is often used for treatment of periodontal diseases and other oral health issues.
Key players in the market are focused on adopting strategies such as partnerships and acquisitions to expand their product portfolio and geographical positioning in the U.S. dental membranes and bone graft substitutes market. For instance, in June 2020, Geistlich Biomaterials announced expansion of their portfolio of regenerative and complimentary products through a new distribution partnership with Osteogenics Biomedical in the U.S. Furthermore, in September 2021, Straumann Group, a global provider of denture and orthodontic solutions, announced the establishment of a strategic partnership with Aspen Dental Management, Inc. (ADMI) to provide dental implant solutions to more than 1,000 ADMI affiliated offices across the U.S.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.